Genetic Technologies Limited (GNTLF)
| Previous close | 0.0007 |
| Open | 0.0007 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0007 - 0.0007 |
| 52-week range | 0.0007 - 6.3400 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 80,791 |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireGenetic Technologies Announces $2 Million Registered Direct Offering
MELBOURNE, Australia, April 19, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies"), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each representing thirty (30) ordinar
- GlobeNewswire
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand. The proprietary-developed tests will provide invaluable information to medical oncologists,
- GlobeNewswire
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the company’s latest milestones along with our clinical adoption of the Company’s groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in Australia. The geneType team has achieved clinical proof of concept in key
